Open AccessUstekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
Author(s) -
Viola Anna,
Muscianisi Marco,
Macaluso Fabio S,
Ventimiglia Marco,
Cappello Maria,
Privitera Antonino C,
Magnano Antonio,
Pluchino Dario,
Magrì Giovanni,
Ferracane Concetta,
Mocciaro Filippo,
Garufi Serena,
Giuffrida Enrica,
Costantino Giuseppe,
Fiocco Gabriele,
Grova Mauro,
Guida Laura,
Alibrandi Angela,
Orlando Ambrogio,
Fries Walter
Publication year - 2021
Publication title -
jgh open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 8
ISSN - 2397-9070
DOI - 10.1002/jgh3.12502
Subject(s) - ustekinumab , medicine , crohn's disease , discontinuation , cohort , cohort study , inflammatory bowel disease , disease , gastroenterology , adalimumab
Background and Aim Ustekinumab is approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Italian real‐life data are scarce, so the aim of this study was to assess the effectiveness and safety of ustekinumab in an Italian cohort of CD patients. Methods Data of patients with CD who started using ustekinumab were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. Primary end‐points were steroid‐free clinical remission at 8, 24, and 52 weeks of therapy and reduction of C‐reactive protein. Secondary end‐points were treatment response, treatment persistence at 12 months, and safety. Results A total of 131 patients (males 56%; mean age 46 years ± 15) were included. All patients were biologics experienced except for one. At 24 and 52 weeks, 40% and 43% of patients achieved steroid‐free clinical remission, and 64% and 62% had clinical response, respectively. At the end of follow‐up, there was a significant reduction of steroid use ( P = 0.012) and of the Harvey‐Bradshaw Index ( P = 0.001). The probability of persistence in therapy with ustekinumab after 12 months of treatment was 89%. The only factor associated with discontinuation was older age. Conclusions Data from our real‐life cohort of treatment‐refractory CD patients suggest the satisfactory effectiveness and safety profile of ustekinumab.